Authors


Vera Vavinskaya, MD

Latest:

Evaluation and Management of Testicular Cancer After Late Relapse

The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.


Solange Peters, MD, PhD

Latest:

Solange Peters, MD, PhD, Reviews Evolving Treatment Trends in Lung Cancer

“Be courageous: Your work will be recognized, and everything is about [the] work in the end.”


Lisa Sprod, PhD, MPH

Latest:

Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier

Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.



Amy A. Ayers, MPH

Latest:

Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical Trials

A multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.


Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®

Latest:

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.


Davit Dallakyan MD, PhD

Latest:

How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.




Farshid Dayyani, MD, PhD

Latest:

Farshid Dayyani, MD, PhD, Discusses Multidisciplinary Approach to Research on Treatment for Gastroesophageal Adenocarcinoma

A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.


Daniel Ahn, DO

Latest:

Advanced HCC: Key Takeaways

Key opinion leaders summarize essential takeaways and highlight unmet needs in the hepatocellular carcinoma treatment landscape.



Lilit Sargsyan, MD

Latest:

How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.


Joanna Roopkumar, MD

Latest:

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.


Raoul S. Concepcion, MD, FACS

Latest:

Optimization of Genetic Testing for mCRPC

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.



Leland Chung, PhD

Latest:

Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.



Brett L. Ecker, MD

Latest:

The Effect of Multidisciplinary Teams for Advancing Research in NETs

Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.


Xianyan Chen, MD

Latest:

Survival of Patients With Inoperable Non–Small Cell Lung Cancer With Baseline Severe Pulmonary Dysfunction: Impacts of Thoracic Radiotherapy and Predictive Analysis for Acute Radiation Pneumonitis

Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.



A. Gabriella Wernicke, MD, MSc

Latest:

ctDNA Data in Gynecologic Cancer RT Population May Be Hypothesis-Generating

A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.


Joanna L. Langner, MS

Latest:

Evaluation and Management of Testicular Cancer After Late Relapse

The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.


Seth Felder, MD

Latest:

Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT Trial

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.



Russ Conroy

Latest:

X-ray Brachytherapy Sustains Organ Preservation in Early Rectal Cancer

Data from the phase 3 OPERA trial support contact X-ray brachytherapy boost as a treatment option for preserving organs in smaller rectal adenocarcinoma tumors.


Caroline Seymour

Latest:

Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML

For patients with HMA–naive chronic myelomonocytic leukemia, an IO-202 combo demonstrated durable responses, a phase 1b study found.



Hannah Clarke

Latest:

EV-302 PRO Outcomes Find Consistent Efficacy Data in Urothelial Carcinoma

Patient-reported outcomes from the EV-302 trial found consistent efficacy and safety outcomes for patients with urothelial carcinoma.


Shebli Atrash, MD

Latest:

Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center

Panelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.